Company Analysis Apellis Pharmaceuticals, Inc.
1. Summary
Advantages
- The stock's return over the last year (28.3%) is higher than the sector average (-4.16%).
Disadvantages
- Price (25.16 $) is higher than fair price (23.74 $)
- Dividends (0%) are below the sector average (0.5148%).
- Current debt level 53.08% has increased over 5 years from 40.34%.
- The company's current efficiency (ROE=-93.55%) is lower than the sector average (ROE=109.03%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Apellis Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 2.1% | -2.8% | -0.2% |
| 90 days | -10.6% | -3.1% | 3.9% |
| 1 year | 28.3% | -4.2% | 21.1% |
APLS vs Sector: Apellis Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 32.46% over the past year.
APLS vs Market: Apellis Pharmaceuticals, Inc. has outperformed the market by 7.21% over the past year.
Stable price: APLS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: APLS with weekly volatility of 0.5443% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (25.16 $) is higher than the fair price (23.74 $).
Price is higher than fair: The current price (25.16 $) is 5.6% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-14.97) is higher than that of the sector as a whole (-284.59).
P/E vs Market: The company's P/E (-14.97) is higher than that of the market as a whole (-77.4).
5.3. P/BV
P/BV vs Sector: The company's P/BV (17.29) is lower than that of the sector as a whole (262.42).
P/BV vs Market: The company's P/BV (17.29) is lower than that of the market as a whole (52.24).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (5.06) is lower than that of the sector as a whole (60.36).
P/S vs Market: The company's P/S indicator (5.06) is lower than that of the market as a whole (138.62).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-25.96) is lower than that of the sector as a whole (11.97).
EV/Ebitda vs Market: The company's EV/Ebitda (-25.96) is higher than that of the market as a whole (-48.38).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -8.53% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-8.53%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.85%).
6.4. ROE
ROE vs Sector: The company's ROE (-93.55%) is lower than that of the sector as a whole (109.03%).
ROE vs Market: The company's ROE (-93.55%) is lower than that of the market as a whole (-10.3%).
6.6. ROA
ROA vs Sector: The company's ROA (-23.64%) is lower than that of the sector as a whole (-2.42%).
ROA vs Market: The company's ROA (-23.64%) is lower than that of the market as a whole (39.94%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-121.89%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (-121.89%) is lower than that of the market as a whole (8.78%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5148%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Selling More insider purchases by 1014.76% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 21.10.2025 | Sullivan Timothy Eugene Chief Financial Officer |
Sale | 28.03 | 28 030 | 10 000 |
| 21.10.2025 | Sullivan Timothy Eugene Chief Financial Officer |
Purchase | 10.03 | 10 030 | 10 000 |
| 10.10.2025 | Dunlop A. Sinclair Director |
Sale | 23.72 | 73 750 | 31 092 |
| 30.09.2025 | Dunlop A. Sinclair Director |
Sale | 22.58 | 702 057 | 31 092 |
| 19.09.2025 | Dunlop A. Sinclair Director |
Sale | 22.95 | 713 561 | 31 092 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
